COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 1 for:    NCT03012581
Previous Study | Return to List | Next Study

Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types (AcSé)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03012581
Recruitment Status : Recruiting
First Posted : January 6, 2017
Last Update Posted : November 1, 2019
National Cancer Institute, France
Ligue contre le cancer, France
Bristol-Myers Squibb
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 2023
Estimated Study Completion Date : December 2023